Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2015

View Archived Issues

JNJ-54861911: promising drug candidate provides stable Abeta reduction

LPCAT-1 implicated in the evolution and progression of breast cancer

Garvan Institute scientists receive support from the Michael J. Fox Foundation

Ocata Therapeutics licenses iPSC technology from Allele Biotechnology

PET imaging of CD4/sr39tk mice enables in vivo tracking of T cells

Novel radiolabeled anti-PSMA nanobody for detection and treatment of prostate cancer

BioLineRx reports topline data for novel stem cell mobilization treatment

Inception 2 patents dual PPARalpha and -delta antagonists

Alexar Therapeutics presents new LXR-beta modulators

NGM Biopharmaceuticals reports phase II data for NGM-282 in primary biliary cirrhosis

Lupin and Indian Rotary Club launch campaign against tuberculosis

Merck & Co. designs small-molecule inhibitors of Hdm2-p53 interaction

Signum Dermalogix licenses SIG-990 to Dermata Therapeutics

Trelagliptin gains first approval in Japan

Daewoong Pharmaceutical presents novel antifungals

Carna Biosciences discloses novel BTK inhibitors

Roche reports development of CB2 receptor agonists

Cladribine receives U.S. orphan drug designation for neuromyelitis optica

Japan Tobacco describes new RORgamma antagonists

European Commission approves Mysimba for weight management

Japanese approval sought for E Keppra as adjunctive therapy for generalized tonic-clonic seizures

Actelion's Opsumit approved in Japan for pulmonary arterial hypertension

MorphoSys regains rights to MOR-202 from Celgene

Aridis starts clinical development of monoclonal antibody against Pseudomonas aeruginosa

Ebola virus vaccines cAd3-EBOZ and VSV-ZEBOV appear to be safe in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...